JP2004517100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517100A5 JP2004517100A5 JP2002551544A JP2002551544A JP2004517100A5 JP 2004517100 A5 JP2004517100 A5 JP 2004517100A5 JP 2002551544 A JP2002551544 A JP 2002551544A JP 2002551544 A JP2002551544 A JP 2002551544A JP 2004517100 A5 JP2004517100 A5 JP 2004517100A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound according
- trifluoromethylphenyl
- thiazol
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 4
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- SSDUSKOBZBGXRV-UHFFFAOYSA-N 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenyl]methoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(C)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 SSDUSKOBZBGXRV-UHFFFAOYSA-N 0.000 claims 1
- YPDJBRIAQLVHSE-UHFFFAOYSA-N 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propoxy]phenyl]methoxy]propanoic acid Chemical compound S1C(C=2C=CC(=CC=2)C(F)(F)F)=NC(C)=C1C(CC)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 YPDJBRIAQLVHSE-UHFFFAOYSA-N 0.000 claims 1
- OQXJAKNLLGBCNA-UHFFFAOYSA-N 2-methyl-2-[[3-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenyl]methoxy]propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(C)(C)OC1=CC=CC(COC(C)(C)C(O)=O)=C1 OQXJAKNLLGBCNA-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- UQIJWTDYTYTARD-UHFFFAOYSA-N ethyl 2-methyl-2-[[3-[1-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethoxy]phenyl]methoxy]propanoate Chemical compound CCOC(=O)C(C)(C)OCC1=CC=CC(OC(C)C2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)C)=C1 UQIJWTDYTYTARD-UHFFFAOYSA-N 0.000 claims 1
- YLVIBAKEWWTIEB-UHFFFAOYSA-N ethyl 2-methyl-2-[[3-[2-[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propan-2-yloxy]phenyl]methoxy]propanoate Chemical compound CCOC(=O)C(C)(C)OCC1=CC=CC(OC(C)(C)C2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)C)=C1 YLVIBAKEWWTIEB-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25707000P | 2000-12-20 | 2000-12-20 | |
| PCT/EP2001/014886 WO2002050047A1 (en) | 2000-12-20 | 2001-12-18 | Substitued oxazoles and thiazoles as hppar alpha agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517100A JP2004517100A (ja) | 2004-06-10 |
| JP2004517100A5 true JP2004517100A5 (enExample) | 2005-12-22 |
Family
ID=22974753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002551544A Pending JP2004517100A (ja) | 2000-12-20 | 2001-12-18 | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7091225B2 (enExample) |
| EP (1) | EP1345916A1 (enExample) |
| JP (1) | JP2004517100A (enExample) |
| AU (1) | AU2002233271A1 (enExample) |
| WO (1) | WO2002050047A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113233D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| WO2003015776A1 (en) * | 2001-08-13 | 2003-02-27 | Janssen Pharmaceutica N.V. | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| JP4276074B2 (ja) * | 2001-10-12 | 2009-06-10 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) * | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| KR100474202B1 (ko) * | 2002-05-04 | 2005-03-08 | 강헌중 | 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체 |
| PT1554240E (pt) * | 2002-10-21 | 2009-06-17 | Janssen Pharmaceutica Nv | Tetralinas e indanos substituídos e sua utilização |
| KR20050067419A (ko) * | 2002-10-21 | 2005-07-01 | 얀센 파마슈티카 엔.브이. | 치환된 테트라린 및 인단으로의 ｘ 증후군의 치료 |
| RS20050318A (sr) * | 2002-10-21 | 2007-09-21 | Janssen Pharmaceutica N.V., | Supstituisani tetralini i indani |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| CN104958270A (zh) * | 2004-08-25 | 2015-10-07 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
| RU2371437C2 (ru) * | 2004-12-31 | 2009-10-27 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | Селенорганические соединения и их применение |
| RU2392274C2 (ru) * | 2005-02-25 | 2010-06-20 | Сеул Нэшнл Юниверсити Индастри Фаундейшн | Тиазольные производные в качестве лигандов ppar-дельта и способ их получения |
| PL1968601T3 (pl) | 2006-01-05 | 2012-03-30 | Essentialis Inc | Sole związków otwierających kanały potasowe ATP i ich zastosowanie |
| KR20090066289A (ko) | 2006-09-08 | 2009-06-23 | 로드아일랜드하스피틀 | 알코올 유발성 뇌 질환의 치료, 예방 및 역행 |
| JP2010532383A (ja) * | 2007-07-02 | 2010-10-07 | エッセンシャリス，インク． | カリウムａｔｐチャネル開口薬の塩およびその使用 |
| EP2404430B1 (en) * | 2009-03-05 | 2016-11-02 | Telecom Italia S.p.A. | Distributed system for storing digital data |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4345230B2 (ja) * | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| AU3113902A (en) * | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
-
2001
- 2001-12-18 WO PCT/EP2001/014886 patent/WO2002050047A1/en not_active Ceased
- 2001-12-18 EP EP01984857A patent/EP1345916A1/en not_active Ceased
- 2001-12-18 AU AU2002233271A patent/AU2002233271A1/en not_active Abandoned
- 2001-12-18 US US10/451,298 patent/US7091225B2/en not_active Expired - Fee Related
- 2001-12-18 JP JP2002551544A patent/JP2004517100A/ja active Pending